Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4836544 | 0.89 | KDM4E (0.46) | TSHRKDM4EALDH1A1TP53CYP3A4 | |
| SCHEMBL4832867 | 0.89 | ACHE (0.40) | SIRT5TSHRKDM4EALDH1A1TP53 | |
| SCHEMBL4839424 | 0.89 | MAPK8 (0.46) | TSHRKDM4EALDH1A1TP53CYP3A4 | |
| SCHEMBL4837847 | 0.89 | KDM4E (0.43) | SIRT5TSHRKDM4EALDH1A1TP53 | |
| SCHEMBL14268895 | 0.86 | ACHE (0.47) | TSHRKDM4EALDH1A1TP53CYP3A4 | |
| SCHEMBL5428806 | 0.85 | TSHR (0.37) | SIRT5TSHRKDM4EALDH1A1TP53 | |
| SCHEMBL4832652 | 0.84 | RAB9A (0.51) | TSHRKDM4EALDH1A1HSD17B10GBA1 | |
| SCHEMBL4832147 | 0.84 | SIGMAR1 (0.47) | TSHRKDM4EALDH1A1HSD17B10RAB9A | |
| SCHEMBL4829629 | 0.83 | ACHE (0.40) | TSHRKDM4EALDH1A1TP53CYP3A4 | |
| SCHEMBL14600548 | 0.83 | IDO1 (0.47) | TSHRKDM4EALDH1A1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173032-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-02-06 | — | — | US | claimed |
| EP-1436266-A4 | METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS | REDDY US THERAPEUTICS INC (US) | 2004-12-22 | — | — | EP | claimed |
| EP-1436266-A2 | METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS | Reddy US Therapeutics, Inc. (US) | 2004-07-14 | — | — | EP | claimed |
| US-20040077648-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-04-22 | — | — | US | claimed |
| WO-2003024926-A2 | METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS | REDDY US THERAPEUTICS, INC. (US) | 2003-03-27 | — | — | WO | claimed |
| US-7335656-B2 | Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis | REDDY US THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335656-B2 | Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis | REDDY US THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335656-B2 | Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis | REDDY US THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335770-B2 | Triazine compounds and their analogs, compositions, and methods | REDDY U5 THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335770-B2 | Triazine compounds and their analogs, compositions, and methods | REDDY U5 THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7332490-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332490-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070004729-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20060258641-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-11-16 | — | — | US | disclosed |
| US-7132423-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-7112587-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060172984-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-08-03 | — | — | US | disclosed |
| US-20050137196-A1 | Medical devices employing triazine compounds and compositions thereof | NATIONAL BANK OF CANADA (CA) | 2005-06-23 | — | — | US | disclosed |
| US-20050124619-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-06-09 | — | — | US | disclosed |
| US-20050113341-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004729-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | SIRT5 1539/4885TSHR 2758/4885KDM4E 3314/4885 |
| US-20050137196-A1 | Medical devices employing triazine compounds and compositions thereof | PTGIS, AREG, TGFB1 | SIRT5 2050/4885TSHR 1630/4885KDM4E 3030/4885 |
| US-20060258641-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | SIRT5 1539/4885TSHR 2758/4885KDM4E 3314/4885 |
| US-20050113341-A1 | Medical devices employing triazine compounds and compositions thereof | PTGIS, AREG, TGFB1 | SIRT5 2050/4885TSHR 1630/4885KDM4E 3030/4885 |
| US-20050124619-A1 | Medical devices employing triazine compounds and compositions thereof | PTGIS, AREG, TGFB1 | SIRT5 2050/4885TSHR 1630/4885KDM4E 3030/4885 |
| US-20060172984-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | SIRT5 1539/4885TSHR 2758/4885KDM4E 3314/4885 |
| US-20040077648-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | SIRT5 1539/4885TSHR 2758/4885KDM4E 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.